OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Study population and positivity of EliA, QUANTA Flash, and IIFA in samples obtained from patients undergoing routine checkups and those from rheumatology clinic patients (N=406)

Sample details EliA-positive ( > 1.0 ratio) N (%) QUANTA Flash-positive ( ≥ 20.0 CU) N (%) IIFA-positive ( ≥ 1 : 80) N (%)
Patients undergoing routine checkups (N = 206) 10 (4.9) 17 (8.3) -
Rheumatology clinic patients (N = 200) 97 (48.5) 104 (52.0) 119 (59.5)
AARD (N = 109) 83 (76.1) 90 (82.6) 96 (88.1)
SLE (N = 72) 52 (72.2) 58 (80.6) 62 (86.1)
SSc (N = 11) 10 (90.9) 10 (90.9) 11 (100.0)
MCTD (N = 6) 6 (100.0) 6 (100.0) 6 (100.0)
SjS (N = 19) 15 (78.9) 16 (84.2) 16 (84.2)
PM/DM (N = 1) 1 (100.0) 1 (100.0) 1 (100.0)
CTD (N = 14) 6 (42.9) 5 (35.7) 8 (57.1)
RA (N = 14) 2 (14.3) 2 (14.3) 3 (21.4)
Non-rheumatic disease (N = 63) 5 (7.9) 6 (9.5) 12 (19.0)

Abbreviations: AARD, antinuclear antibody-associated rheumatic disease; CTD, connective tissue disease; CU, chemiluminescent units; IIFA, indirect immunofluorescence assay; MCTD, mixed connective tissue disease; N, number of samples; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SjS, primary Sjögren’s syndrome; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.

Ann Lab Med 2022;42:63~70

© Ann Lab Med